Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery libraries including both (1) highly diverse synthetic naïve antibody phage display libraries and (2) target class specific antibody phage display libraries against difficult-to-drug targets. In this talk, Aaron Sato, CSO, will present several POC data on each member of their Library of Libraries. For some of the targets, the power of selecting multiple libraries against each target will be highlighted.

A Comprehensive Guide to Antibody Discovery and Development. Considerations and approaches for the Biopharma Industry.

Monoclonal antibodies have become the preferred therapeutic modality for cancer, infectious diseases, inflammatory and autoimmune disorders, and other conditions.   Twist Bioscience is on a mission to support this work, offering a Library of Libraries containing multiple pre-constructed and validated libraries against many high-value targets with which scientists can build a comprehensive and robust antibody discovery platform. Watch the video  to:   Learn about the Hyperimmune Library for therapeutic development against virtually any target. Hear how the latest libraries are opening new sequence space, allowing researchers to focus on difficult-to-drug targets like GPCRs and ion channels. Review recent work from Twist Biopharma using the Library of Libraries against human ACE2 and the SARS-CoV-2 spike protein to find potently neutralizing candidate antibodies against the SARS-CoV-2 strain of coronavirus in under 4 weeks. Compare options for accessing the Library of Libraries, including licensing or partnering to fully outsource lead discovery.